Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Set Alert for Strategy

Leaner Kabi Drives Higher Savings Goal For Fresenius, China ‘Soft’ In 2024

Fresenius Kabi insists there is a “business plan behind everything” as it divulged a higher cost savings goal for the end of next year, following a fruitful 2023. But queries over margins led the company to stress that it was combatting a variety of uncertainties, especially in China and for its burgeoning biosimilars unit.

Sales & Earnings Strategy

Teva Commits To Dual Branded And Generic Model

Teva’s innovative and generic interests can not only co-exist but are complementary, CEO Richard Francis has set out, in response to questions over whether the Israeli giant would consider splitting its businesses to focus more on branded drugs.

Strategy Generic Drugs

Biocon Eyes 'Foothold To Stronghold' For (b)Humira In US, Pauses RH-Insulin Program

Biocon sees some wins for biosimilar adalimumab in the US and signals more opportunities amid the slower than anticipated build-out for Humira rivals. Chinese competition looms for glargine, but the Indian company declares it “will be competitive if these folks launch.”

Biosimilars Strategy

A $31bn Opportunity? Future Of Biosimilars Inches Closer With Samsung Keytruda Study

Samsung Bioepis is among a small pool of players heading to the clinic for a proposed biosimilar to Merck & Co’s PD-1 mega-blockbuster, as interest and investment rises ahead of patent expiry at the end of the decade.

Biosimilars Clinical Trials

Biogen’s Biosimilars Sales Rise, But Future Still Unknown

Biogen has yet again hinted about “strategic alternatives” for its biosimilars business albeit with no clear future plans, while its branded multiple sclerosis portfolio fights off generic and biosimilar competitors.

Biosimilars Strategy

Private Equity Firm Acquires Irish Generics Player Chanelle

The private equity firm Exponent has acquired Ireland’s biggest generics producer, Chanelle Pharma, following past media reports of the pharma’s nearing sale, which estimated the price north of €300m.

Deals M & A

Biocon Boosts Biosimilars In Australia With Sandoz Partnership

Biocon Biologics is seeking to bolster its biosimilars business in Australia, recently integrated after being acquired from former owner Viatris, through a deal that will see Sandoz market its Ogivri and Abevmy versions of trastuzumab and bevacizumab.

Deals Biosimilars

No 'Constraining Situation' On Generic Vascepa API, Says Strides MD

Strides intends to keep US momentum going with Amneal-partnered generic Vascepa, where Hikma and Dr. Reddy’s have filed antitrust suits against Amarin over API supply. Meanwhile, the founder re-iterated ambitious goals set for Stelis and its CDMO business.

Strategy Ingredients

Gedeon Richter Investment In Formycon Opens Up Collaboration Opportunities

Gedeon Richter has agreed to acquire a stake of just over 9% in Formycon. The deal “opens up the possibility of jointly leveraging long-term strategic opportunities” while providing Formycon with more than €80m to invest in its biosimilar development projects.

Deals Biosimilars

Who’s Hired? Sandoz Freshens Up Directors Board After Pivotal Year

Sandoz nominated a new director candidate ahead of its annual meeting and Lantheus welcomed a familiar face as the new CEO. Meanwhile, Mallinckrodt strengthened its board with four new directors and Hikma announced another appointment this year.

Executive Changes Leadership

Rani Shares Positive Oral Ustekinumab Data After Last Year’s Challenges

Rani Therapeutics announced positive topline results from a Phase I trial of its oral Stelara biosimilar, moving it further in a crowded market with fierce competition.

Biosimilars Clinical Trials

Henlius Raises Stakes In Denosumab Race With Phase I Completion

Shanghai Henlius Biotech announced the successful completion of a Phase I study of its biosimilar HLX14 to Prolia/Xgeva, paving the way for EU and US approval applications later in 2024.

Biosimilars Clinical Trials

‘Stabilize’ Is The Message For Teva In North America As It Plots Return To Growth

“The value that generics bring to the healthcare industry, to the hospitals, to society is not reflected in the price that we can sell them at,” Teva told investors, as it outlined plans to mitigate erosion with a slate of big-ticket launches in the US.

Strategy Sales & Earnings

Celltrion Files Tocilizumab In US

Celltrion has become the latest firm to file for a tocilizumab biosimilar in the US, submitting its CT-P47 candidate to the FDA.

Biosimilars United States

For Sale, Buyer Sought: Teva Confirms API Unit Is On The Block

Teva had told investors last year that it believed it was stymying its API unit’s growth by not allowing it to stand taller on its own two feet. Now the Israeli firm has confirmed that the business, TAPI, is up for sale.

Deals Strategy

USP And Dexcel Pick Up Teva OTC Brands

Teva has struck a deal with USP in Poland that will see the Israeli company divest multiple consumer health brands. Meanwhile, Dexcel Pharma has acquired eight OTC brands from Teva in the UK.

Deals Strategy
See All